Structure Therapeutics: A High-Risk, High-Reward Bet On The Next GLP-1 BlockbusterSeeking Alpha • 03/27/26
Structure Therapeutics' GLP-1 Agonist Could Be A Potential Acquisition TargetSeeking Alpha • 03/17/26
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1 TranscriptSeeking Alpha • 03/16/26
Weight Loss Pill from Structure Therapeutics Trimmed the Most Pounds Yet. Is the Biotech a Takeover Candidate?Barrons • 03/16/26
Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%Benzinga • 03/16/26
Why Weight-Loss Contender Structure Therapeutics Just Shot SkywardInvestors Business Daily • 03/16/26
Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, AleniglipronGlobeNewsWire • 03/16/26
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 MillionThe Motley Fool • 02/27/26
Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent HighlightsGlobeNewsWire • 02/26/26
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million PositionThe Motley Fool • 02/25/26
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?Seeking Alpha • 02/18/26
This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.The Motley Fool • 02/05/26
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1sCNBC • 01/21/26
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025Zacks Investment Research • 12/22/25
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSsGlobeNewsWire • 12/11/25
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded WarrantsGlobeNewsWire • 12/10/25
GPCR Stock Soars 102% on Strong Phase II Obesity Data for AleniglipronZacks Investment Research • 12/09/25